FARN
vs
F
FTSE All Share Index
FARN
Over the past 12 months, FARN has underperformed FTSE All Share Index, delivering a return of 0% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
FARN vs FTSE All Share Index
Performance Gap
FARN vs FTSE All Share Index
Performance By Year
FARN vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Faron Pharmaceuticals Oy
Glance View
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. The company is headquartered in Turku, Lansi-Suomen and currently employs 37 full-time employees. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.
